Ridgeback Biotherapeutics
Biotechnology company founded in 2016 focused on developing therapeutics for emerging infectious diseases. Operates across discovery, preclinical development, clinical trials (Phases I–III), regulatory submissions and post-approval access programs, and collaborates with academic, government, and non-governmental organizations.
Industries
Nr. of Employees
small (1-50)
Ridgeback Biotherapeutics
Coconut Creek, Florida, United States, North America
Products
EBANGA (ansuvimab-zykl, mAb114)
Human monoclonal antibody indicated for treatment of infection caused by Zaire ebolavirus in adults and pediatric patients; obtained FDA approval in December 2020 and distributed with global access arrangements for outbreak regions.
Lagevrio (molnupiravir)
Oral broad‑spectrum direct-acting antiviral small molecule developed for treatment of COVID-19; advanced through Phase 1/2 and into Phase 3, with Emergency Use Authorization granted by the U.S. FDA for treatment of high‑risk adults with mild-to-moderate COVID-19.
EBANGA (ansuvimab-zykl, mAb114)
Human monoclonal antibody indicated for treatment of infection caused by Zaire ebolavirus in adults and pediatric patients; obtained FDA approval in December 2020 and distributed with global access arrangements for outbreak regions.
Lagevrio (molnupiravir)
Oral broad‑spectrum direct-acting antiviral small molecule developed for treatment of COVID-19; advanced through Phase 1/2 and into Phase 3, with Emergency Use Authorization granted by the U.S. FDA for treatment of high‑risk adults with mild-to-moderate COVID-19.
Services
Expanded access program administration
Consideration and processing of physician requests for investigational medicines when clinical trials are not an option; evaluation of benefit-risk, documentation review, and regulatory coordination.
Licensing and collaboration facilitation
Negotiation and management of licenses and partnerships with academic labs, government agencies, and industry collaborators to advance therapeutics from discovery to clinic.
Expanded access program administration
Consideration and processing of physician requests for investigational medicines when clinical trials are not an option; evaluation of benefit-risk, documentation review, and regulatory coordination.
Licensing and collaboration facilitation
Negotiation and management of licenses and partnerships with academic labs, government agencies, and industry collaborators to advance therapeutics from discovery to clinic.
Expertise Areas
- Emerging infectious disease therapeutics
- Antiviral drug development
- Monoclonal antibody therapeutics
- Clinical trial management (Phases I–III)
Key Technologies
- Monoclonal antibody therapeutics
- Oral small-molecule antiviral development
- Clinical trial platform operations
- Regulatory submission processes (IND, EUA)